beta-Lapachone CAS: 4707-32-8
MF: C15H14O3
MW: 242.27
A selective DNA topoisomerase I inhibitor.

β-Lapachone (CAS 4707-32-8)

  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getAggregateRating, 136ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
5
1
4
0
3
0
2
0
1
0
Synonym 3,4-Dihydro-2,2-dimethyl-2H-naphtho[1,2-b]pyran-5,6-dione
Anwendungen A selective DNA topoisomerase I inhibitor
CAS Nummer: 4707-32-8
Reinheit: ≥98%
Molekulargewicht: 242.27
Summenformel: C15H14O3
* Schauen Sie auf das Analysezertifikat (CoA), um die genauen Daten (inkl. Wassergehalt) Ihrer Produktionscharge (Lot) zu sehen.
Bewerten Sie dieses Produkt und erhalten Sie 15 CruzCredits

β-Lapachone, a novel Topo I (topoisomerase I) inhibitor, does not stabilize the cleavable complex indicating a novel mode of action, unlike camptothecin (sc-200871). Apoptosis has been demonstrated in HL-60 and human prostate cancer cells treated with β-Lapachone via a p53-independent mechanism and cell cycle arrest at G0/G1,2. β-Lapachone has been observed to accelerate wound healing by increasing cell proliferation in cells such as: keratinocytes, fibroblasts and endothelial while also increasing the migration of fibroblasts and endothelial cells. β-Lapachone has exhibited anti-inflammatory properties by suppressing the NF-κB activation by blocking IκBα degradation and downregulating the ERK, p38 mitogen-activated protein kinase and Akt pathway.


Literaturhinweise

1. Planchon, S M., et al., 1995. Beta-lapachone-mediated apoptosis in human promyelocytic leukemia (HL-60) and human prostate cancer cells: a p53-independent response. Cancer research. 55(17): 3706-11. PMID: 7641180
2. Li, C J., et al., 1993. beta-Lapachone, a novel DNA topoisomerase I inhibitor with a mode of action different from camptothecin. The Journal of biological chemistry. 268(30): 22463-8. PMID: 8226754
3. Choi, Byung Tae., et al., 2003. beta-Lapachone-induced apoptosis is associated with activation of caspase-3 and inactivation of NF-kappaB in human colon cancer HCT-116 cells. Anti-cancer drugs. 14(10): 845-50. PMID: 14597880
4. Moon, Dong-Oh., et al., 2007. Anti-inflammatory effects of beta-lapachone in lipopolysaccharide-stimulated BV2 microglia. International immunopharmacology. 7(4): 506-14. PMID: 17321474
5. Kung, Hsiu-Ni., et al., 2008. In vitro and in vivo wound healing-promoting activities of beta-lapachone. American journal of physiology. Cell physiology. 295(4): C931-43. PMID: 18650264
6. Dong, Guang Zhi., et al., 2010. Beta-lapachone suppresses radiation-induced activation of nuclear factor-kappaB. Experimental & molecular medicine. 42(5): 327-34. PMID: 20200474

Gebrauch :
Store, as supplied, at room temperature for up to 1 year. Store solutions at - 20°C for up to 3 months.
Aggregatzustand :
Solid
Löslichkeit :
Soluble in DMSO (>25 mg/ml), ethanol (20 mg/ml), chloroform, and DMF.
LAGERUNG: :
Store at -20° C
Schmelztemperatur :
~151-153° C (dec.)
Sidepunkt :
~381.4° C at 760 mmHg (Predicted)
Dichte :
1.25 g/cm3 (Predicted)
Brechungsindex :
n20D 1.60
Optische Aktivität :
α20/D -43.9°, c = 2 in water
IC50 :
HIV-1 LTR: IC50 = 0.3 µM (human); HOS: IC50 = 1400 nM (human); MDA-MB-435 : IC50 = 0.06 ug.mL-1 (human); HL-60: IC50 = 1650 nM (human)
Ausschließlich für Forschungszwecke. Nicht Geeignet für Verwendung in Diagnostik oder Therapie.
Deutsche WGK :
3
RTECS :
QL6127400
PubChem CID :
3885
MDL-Nummer :
MFCD01712233
Beilstein-Registernummer :
0181499
SMILES :
CC1(CCC2=C(O1)C3=CC=CC=C3C(=O)C2=O)C

SDS (MSDS) herunterladen

Analysenzertifikat

Um PDF-Dokumente zu Drucken oder zu Bearbeiten
benötigen Sie Adobe Acrobat Reader

beta-Lapachone  Publikationen

Lesen Sie wie andere Anwender beta-Lapachone eingesetzt haben. Klicken Sie auf den jeweiligen Eintrag um den entsprechenden PubMed-Abstract abzurufen .

Produktreferenz 1 bis 6 von 6 insgesamt

PMID: # 17609380  Bey, EA. et al. 2007. Proc. Natl. Acad. Sci. USA. 104: 11832-11837.

PMID: # 15044484  Lin, MT et al. 2004. J Biol Chem. 279: 24015-23.

PMID: # 12598645  Li, Y. et al. 2003. Proc. Natl. Acad. Sci. U.S.A. 100: 2674-2678.

PMID: # 9927052  Shiah, SG. et al. 1999. Cancer Res. 59: 391-398.

PMID: # 9927052  Shiah, SG. et al. 1999. Cancer Res. 59: 391-398.

PMID: # 2740334  Boothman, DA. et al. 1989. Proc. Natl. Acad. Sci. U.S.A. 86: 4963-4967.

Produktreferenz 1 bis 6 von 6 insgesamt
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getContent, 130ms
  • QUESTIONS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;
  • bvseo_sdk, java_sdk, bvseo-3.2.0
  • CLOUD, getReviews, 10ms
  • REVIEWS, PRODUCT
  • bvseo-msg: The resource to the URL or file is currently unavailable.;

Santa Cruz Biotechnology, Inc. ist weltweit führend in der Entwicklung von Produkten für den biomedizinischen Forschungsmarkt. Rufen Sie uns an, gebührenfrei unter 00800 4573 8000. .
Copyright © 2007-2020, Santa Cruz Biotechnology, Inc. Alle Rechte vorbehalten. "Santa Cruz Biotechnology", das Santa Cruz Biotechnology, Inc. Logo, "Santa Cruz Animal Health", "San Juan Ranch", "Supplement of Champions", das San Juan Ranch Logo, "Ultracruz", "Chemcruz", "Immunocruz", "Exactacruz" und "EZ Touch" sind eingetragene Warenzeichen der Santa Cruz Biotechnology, Inc. Alle genannte Warenzeichen sind Eigentum der jeweiligen Inhaber. Alle Rechte vorbehalten.